Year: 2023

Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial

Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b,...

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

BOSTON, March 24, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis,...

error: Content is protected !!